inotuzumab ozogamicin sold brand name besponsa antibodydrug conjugate medication used treat relapsed refractory bcell precursor acute lymphoblastic leukemia medication consists humanized monoclonal antibody inotuzumab linked cytotoxic agent class calicheamicins called drug discovered scientists collaborating celltech wyeth developed pfizer acquired wyeth us food drug administration fda considers firstinclass inotuzumab ozogamicin used treat relapsed refractory bcell precursor acute lymphoblastic administered intravenous infusion doctors office studies pregnant animals drug caused harm fetus doses less used clinically drug tested pregnant women pregnant women take inotuzumab ozogamicin must become pregnant taking unknown drug metabolites secreted breast milk women breastfeed taking wait two months last dose start drug prolongs qt interval people used caution people heart us label use inotuzumab ozagamicin carries fda black box warning concerning risk liver toxicity particular hepatic venoocclusive disease vod fatal risk higher people take drug hematopoietic stem cell transplantation hsct people die hsct following treatment drug people hsct taking chemotherapies risk gets higher rounds treatment inotuzumab ozogamicin common serious adverse reactions people taking drug clinical trial leading approval infections loss neutrophils fever hemorrhage stomach pain fever vod tiredness people following adverse reactions loss platelets loss neutrophils infections anemia leukopenia tiredness hemorrhage fever nausea headache loss neutrophils fever elevated transaminases stomach pain jaundice needed people also loss appetite vomiting diarrhea mouth sores constipation chills injection site antibody component inotuzumab ozogamicin binds receptors expressed mostly b cells whole conjugate drawn cell ozogamicin cleaved antibody acidic environment ozogamicin eventually travels nucleus breaks dna causing cell inotuzumab ozogamicin consists humanized monoclonal antibody inotuzumab linked cytotoxic agent class calicheamicins called ozogamicin nacetylgammacalicheamicin includes linker called acbut toxin gemtuzumab ozogamicin arose linker carbonylcontaining carboxylic antibody originally called created grafting complementaritydetermining regions framework residues murine mab onto human acceptor celltech wyeth entered collaboration develop antibodydrug humanized antibody portion generated celltech dna encoding transfected cho cells sent wyeth chemists expressed purified antibodies conjugated linker cytotoxin work published celltech acquired ucb wyeth acquired pfizer may phase iii trial patients relapsed refractory aggressive nonhodgkin lymphoma nhl candidates intensive highdose chemotherapy terminated inotuzumab ozogamicin approved european commission fda treatment adults relapsed refractory bcell precursor acute lymphoblastic leukemia trade name besponsa httpsenwikipediaorgwikiinotuzumabozogamicin